STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: However, high concentrations of this compound was required to disrupt STAT5 DNA binding and P-Y-STAT5 in CML and Burkitt’s lymphoma (BL) cell lines, respectively [322].